Skip to main content
Premium Trial:

Request an Annual Quote

Accler8 s Q1 Revenues Down, Net Loss Up 3 Percent

NEW YORK, Dec. 16 (GenomeWeb News) - Accelr8 Technology today said that total revenue for its first fiscal quarter fell to $21,724 revenue from $22,284 in the year-ago period.


Accler8's said 90 percent of its net revenues in the quarter were from sales to Schott, with whom it closed a microarray slide surface chemistry licensing agreement on Dec. 6.


Net loss for the quarter ending Oct. 31, meantime, increased to $509,800 from $494,761 year over year, the Denver-based company reported today.


The company reported research and development expenses of $203,000 for the quarter, a 42-percent increase over the $143,000 reported for the same quarter last year.


Acceler8 reported cash and cash equivalents of $6.8 million on hand as of Oct. 31.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.